Target intelligence / Profile preview

Probable ATP-dependent RNA helicase DDX10 (DDX10)

Target
DDX10
Molecular classification
Enzyme, RNA helicase, DEAD-box RNA helicase family, RNA-binding protein
01

Overview

Probable ATP-dependent RNA helicase DDX10 (DDX10) is an enzyme belonging to the DEAD-box RNA helicase family, characterized by conserved motifs that mediate ATP-dependent RNA unwinding and remodeling[5]. It is crucial for cellular and stem cell homeostasis, ribosome biogenesis, and RNA metabolic processes, including ribosomal RNA (rRNA) processing, particularly the maturation of 18S rRNA and assembly of the small ribosomal subunit[1]. DDX10 localizes predominantly to the nucleolar dense fibrillar and granular components, where it binds and regulates 45S rRNA. Degradation or dysfunction of DDX10, as seen in disease states or via NUP98-DDX10 fusion in cancers, impairs ribosome biogenesis and protein synthesis, leading to cell cycle arrest and apoptosis[1][3]. DDX10 is also involved in liquid-liquid phase separation (LLPS), essential for formation of nucleolar structures and efficient ribosome production[1]. Dysregulation or fusion involving DDX10 contributes to leukemogenesis and is associated with abnormal expression in various solid tumors, modulating cell proliferation and tumorigenic signaling pathways[3].

Other names
DDX10HRH-J8Dbp4DEAD box protein 10DEAD (Asp-Glu-Ala-Asp) box polypeptide 10DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 10 (RNA helicase)DDX10-NUP98 fusion protein type 2
02

Biological functions

Ribosome biogenesisRNA metabolism (transcription, splicing, export, translation, turnover)Cell cycle progressionCell fate maintenanceApoptosis regulationLiquid-liquid phase separation (LLPS) in nucleolus
03

Disease associations

Cancer (multiple types, notably acute myelocytic leukemia through NUP98-DDX10 fusion, also implicated in osteosarcoma, lung cancer, chondrosarcoma/glioma, colorectal cancer)Hematologic malignanciesPossible roles in neurodevelopmental disorders (e.g., Autism Spectrum Disorder reported)
04

Safety considerations

Therapeutic targeting may impact essential ribosome biogenesis and global protein synthesis, risking cytotoxicity and cell viability.Disruption causes cell cycle arrest and apoptosis.Changes in nucleolar structure/function, affecting homeostasis.
05

Biomarkers

NUP98-DDX10 fusion protein (for acute myelocytic leukemia)

Beyond the preview

Go deeper on Probable ATP-dependent RNA helicase DDX10 (DDX10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX10 (DDX10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call